Journal article icon

Journal article

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV- 2 variants of concern

Abstract:

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF- 332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid inte...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41467-022-28354-0

Authors


More by this author
Role:
Author
ORCID:
0000-0001-9771-7312
More by this author
Role:
Author
ORCID:
0000-0002-6380-4917
More by this author
Role:
Author
ORCID:
0000-0002-9265-6028
More by this author
Role:
Author
ORCID:
0000-0001-8820-6617
More by this author
Role:
Author
ORCID:
0000-0002-3872-6558
Publisher:
Springer Nature
Journal:
Nature Communications More from this journal
Volume:
13
Issue:
1
Article number:
719
Place of publication:
England
Publication date:
2022-02-15
Acceptance date:
2022-01-18
DOI:
EISSN:
2041-1723
Pmid:
35169114

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP